AU7298398A - Enhanced effects for hapten conjugated therapeutics - Google Patents
Enhanced effects for hapten conjugated therapeuticsInfo
- Publication number
- AU7298398A AU7298398A AU72983/98A AU7298398A AU7298398A AU 7298398 A AU7298398 A AU 7298398A AU 72983/98 A AU72983/98 A AU 72983/98A AU 7298398 A AU7298398 A AU 7298398A AU 7298398 A AU7298398 A AU 7298398A
- Authority
- AU
- Australia
- Prior art keywords
- enhanced effects
- hapten conjugated
- therapeutics
- conjugated therapeutics
- hapten
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75267196A | 1996-11-19 | 1996-11-19 | |
| US08/752671 | 1996-11-19 | ||
| PCT/US1997/018475 WO1998022141A2 (en) | 1996-11-19 | 1997-11-06 | Enhanced effects for hapten conjugated therapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU7298398A true AU7298398A (en) | 1998-06-10 |
Family
ID=25027301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU72983/98A Abandoned AU7298398A (en) | 1996-11-19 | 1997-11-06 | Enhanced effects for hapten conjugated therapeutics |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1027073A2 (en) |
| AU (1) | AU7298398A (en) |
| WO (1) | WO1998022141A2 (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030190740A1 (en) | 1998-10-13 | 2003-10-09 | The University Of Georgia Research Foundation, Inc | Stabilized bioactive peptides and methods of identification, synthesis, and use |
| WO2000022112A1 (en) | 1998-10-13 | 2000-04-20 | The University Of Georgia Research Foundation, Inc. | Stabilized bioactive peptides and methods of identification, synthesis and use |
| WO2001032207A1 (en) * | 1998-10-30 | 2001-05-10 | United States Army Medical Research And Materiel Command | Methods for conferring active/passive immunotherapy |
| JP2003518075A (en) * | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | Methods and compositions for extending the elimination half-life of bioactive compounds |
| EP1757311B1 (en) * | 1999-12-24 | 2009-02-11 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| KR101159061B1 (en) | 2001-10-22 | 2012-06-22 | 더 스크립스 리서치 인스티튜트 | Antibody targeting compounds |
| EP2949668B1 (en) | 2005-05-18 | 2019-08-14 | Ablynx N.V. | Improved nanobodies tm against tumor necrosis factor-alpha |
| EP2514767A1 (en) | 2006-12-19 | 2012-10-24 | Ablynx N.V. | Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders |
| AU2007336242B2 (en) | 2006-12-19 | 2012-08-30 | Ablynx N.V. | Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders |
| CA2720763A1 (en) | 2008-04-07 | 2009-10-15 | Ablynx Nv | Amino acid sequences directed against the notch pathways and uses thereof |
| WO2010010119A1 (en) | 2008-07-22 | 2010-01-28 | Ablynx Nv | Amino acid sequences directed against multitarget scavenger receptors and polypeptides |
| MX2011010681A (en) | 2009-04-10 | 2012-01-20 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders. |
| PT2438087T (en) | 2009-06-05 | 2017-08-04 | Ablynx Nv | Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections |
| US9644022B2 (en) | 2009-11-30 | 2017-05-09 | Ablynx N.V. | Amino acid sequences directed against human respiratory syncytial virus (HRSV) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
| EP3309176B1 (en) | 2009-12-14 | 2025-10-01 | Ablynx N.V. | Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use |
| WO2011083141A2 (en) | 2010-01-08 | 2011-07-14 | Ablynx Nv | Method for generation of immunoglobulin sequences by using lipoprotein particles |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| AU2011254557B2 (en) | 2010-05-20 | 2015-09-03 | Ablynx Nv | Biological materials related to HER3 |
| WO2012062713A1 (en) | 2010-11-08 | 2012-05-18 | Novartis Ag | Cxcr2 binding polypeptides |
| UA117218C2 (en) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F |
| WO2012175740A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Immunoglobulin single variable domains directed against ige |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| WO2014087010A1 (en) | 2012-12-07 | 2014-06-12 | Ablynx N.V. | IMPROVED POLYPEPTIDES DIRECTED AGAINST IgE |
| NL2013661B1 (en) | 2014-10-21 | 2016-10-05 | Ablynx Nv | KV1.3 Binding immunoglobulins. |
| WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| CN110177809B (en) | 2016-11-16 | 2023-11-03 | 埃博灵克斯股份有限公司 | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| AU2018277310B2 (en) | 2017-06-02 | 2024-07-11 | Ablynx Nv | Aggrecan binding immunoglobulins |
| JP7369127B2 (en) | 2017-12-28 | 2023-10-25 | ナンジン レジェンド バイオテック カンパニー，リミテッド | Single domain antibodies against TIGIT and variants thereof |
| KR102839330B1 (en) | 2018-01-15 | 2025-07-30 | 난징 레전드 바이오테크 씨오., 엘티디. | Single-domain antibodies to PD-1 and variants thereof |
| US11958903B2 (en) | 2018-03-30 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
| CN117321076A (en) | 2021-02-19 | 2023-12-29 | 美国卫生及公众服务部代表 | Single domain antibodies that neutralize SARS-CoV-2 |
| WO2024083843A1 (en) | 2022-10-18 | 2024-04-25 | Confo Therapeutics N.V. | Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders |
| WO2025034806A1 (en) | 2023-08-08 | 2025-02-13 | Wisconsin Alumni Research Foundation | Single-domain antibodies and variants thereof against fibroblast activation protein |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5888512A (en) * | 1987-01-30 | 1999-03-30 | Board Of Trustees Of The Leland Stanford Junior University | Lymphocyte activity regulation by HLA peptides |
| DE4238416A1 (en) * | 1992-11-13 | 1994-05-19 | Max Planck Gesellschaft | Determination of peptide motifs on MHC molecules |
| JPH09503003A (en) * | 1994-06-16 | 1997-03-25 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | Immunomodulation by class II alpha chain fragments |
| US5753625A (en) * | 1995-05-12 | 1998-05-19 | Sangstat Medical Corporation | Treatment for inhibiting the progression of autoimmune disease |
| WO1997024140A1 (en) * | 1996-01-02 | 1997-07-10 | The Board Of Trustees Of Leland Stanford Junior University | Interaction of hla proteins with members of the hsp70 family of proteins |
| CA2218737C (en) * | 1996-04-10 | 2003-12-16 | Sangstat Medical Corporation | Cytomodulating conjugates of members of specific binding pairs |
-
1997
- 1997-11-06 AU AU72983/98A patent/AU7298398A/en not_active Abandoned
- 1997-11-06 EP EP97949336A patent/EP1027073A2/en not_active Withdrawn
- 1997-11-06 WO PCT/US1997/018475 patent/WO1998022141A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1027073A2 (en) | 2000-08-16 |
| WO1998022141A3 (en) | 1999-01-07 |
| WO1998022141A2 (en) | 1998-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU7298398A (en) | Enhanced effects for hapten conjugated therapeutics | |
| TJ328B (en) | Interferron conjugates | |
| AU7616396A (en) | Substation | |
| AU4721897A (en) | Tetrahydroisoquinoline derivatives | |
| AU4032397A (en) | Imidazoquinazoline derivatives | |
| AU1735497A (en) | Sulfonylureidopyrazole derivatives | |
| AU2186797A (en) | Pharmaceutically useful compounds | |
| AU7002296A (en) | Analgesic composition | |
| AU3867997A (en) | Chromene-3-carboxylate derivatives | |
| AU2956097A (en) | Alkylaminobenzothiazole and -benzoxazole derivatives | |
| AUPO284396A0 (en) | Benzodiazepine derivatives | |
| EP1008579A3 (en) | Cyclopentenebutanol derivatives | |
| HUP9900143A3 (en) | Pharmaceutically useful 3-pyridil-compounds | |
| AU4344696A (en) | Oligonucleotide-dendrimer conjugates | |
| AU4962097A (en) | 2-methoxyphenylpiperazine derivatives | |
| AU2961097A (en) | Substituted pyrazolylpyrazole derivatives | |
| AU1793197A (en) | Pyrazole-4-yl-hetaroyl derivatives | |
| AU5347496A (en) | Ethynylthiazole derivative | |
| AU4296497A (en) | Substituted pyrroles | |
| AU3685097A (en) | N-benzylazolium derivatives | |
| AU3038397A (en) | Neurotransmitters | |
| AU7301296A (en) | Audio-transferred dab | |
| AU4968197A (en) | Novel phenanthridinium derivatives | |
| AU3544297A (en) | Improved ashtray | |
| AU2123797A (en) | 2-thioxotetrahydropyrimidin-4-one derivatives |